In a report released today, Wimal Kapadia from Bernstein maintained a Buy rating on Roche Holding AG (RHHVF), with a price target of CHF380.00. The company’s shares closed last Friday at $342.05.
According to TipRanks.com, Kapadia is ranked #1792 out of 6880 analysts.
Currently, the analyst consensus on Roche Holding AG is a Strong Buy with an average price target of $420.13, representing a 21.0% upside. In a report issued on July 26, UBS also maintained a Buy rating on the stock with a CHF380.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $399.00 and a one-year low of $271.11. Currently, Roche Holding AG has an average volume of 3,870.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
